Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronen Arbel

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Vaccines|August 26, 2022
Vaccinations versus Lockdowns to Prevent COVID-19 MortalityRonen Arbel, Joseph Pliskin
Expert Review of Pharmacoeconomics & Outcomes Research|March 10, 2017
Using lower cost statins improves outcomes for normal cholesterol non-diabetic patientsRonen Arbel, Dan Greenberg
International Journal for Equity in Health|February 26, 2016
Rethinking cost-effectiveness in the era of zero healthcare spending growthRonen Arbel, Dan Greenberg
The American Journal of Cardiology|February 4, 2019
Usefulness of Ezetimibe Versus Evolocumab as Add-On Therapy for Secondary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes MellitusRonen Arbel, Ariel Hammerman, Joseph Azuri
The American Journal of Cardiology|August 5, 2018
Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular MortalityRonen Arbel, Ariel Hammerman, Joseph Azuri
Clinical Drug Investigation|June 8, 2020
Correction to: Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome AnalysisRonen Arbel, Enis Aboalhasan, Ariel Hammerman, et al.
The American Journal of Cardiology|May 18, 2021
Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes MellitusRonen Arbel, Enis Aboalhasan, Ariel Hammerman, et al.
The American Journal of Medicine|January 15, 2021
Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money AnalysisRonen Arbel, Enis Aboalhasan, Ariel Hammerman, et al.
Cancer Letters|February 14, 2026
Validation of "SARS-CoV-2 mRNA Vaccines Sensitize Tumors to Immune Checkpoint Blockade" in an Independent Cohort of 4,407 patientsRonen Arbel, Lior Rokach, Talish Razi, et al.
Journal of Clinical Medicine|January 10, 2026
The Effect of ADHD Stimulant Treatment on Weight Categories in Children and AdolescentsShlomit Yaron, Ronen Arbel, Talish Razi, et al.
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Vaccines|August 26, 2022
Vaccinations versus Lockdowns to Prevent COVID-19 MortalityRonen Arbel, Joseph Pliskin
Expert Review of Pharmacoeconomics & Outcomes Research|March 10, 2017
Using lower cost statins improves outcomes for normal cholesterol non-diabetic patientsRonen Arbel, Dan Greenberg
International Journal for Equity in Health|February 26, 2016
Rethinking cost-effectiveness in the era of zero healthcare spending growthRonen Arbel, Dan Greenberg
The American Journal of Cardiology|February 4, 2019
Usefulness of Ezetimibe Versus Evolocumab as Add-On Therapy for Secondary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes MellitusRonen Arbel, Ariel Hammerman, Joseph Azuri
The American Journal of Cardiology|August 5, 2018
Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular MortalityRonen Arbel, Ariel Hammerman, Joseph Azuri
Clinical Drug Investigation|June 8, 2020
Correction to: Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome AnalysisRonen Arbel, Enis Aboalhasan, Ariel Hammerman, et al.
The American Journal of Cardiology|May 18, 2021
Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes MellitusRonen Arbel, Enis Aboalhasan, Ariel Hammerman, et al.
The American Journal of Medicine|January 15, 2021
Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money AnalysisRonen Arbel, Enis Aboalhasan, Ariel Hammerman, et al.
Cancer Letters|February 14, 2026
Validation of "SARS-CoV-2 mRNA Vaccines Sensitize Tumors to Immune Checkpoint Blockade" in an Independent Cohort of 4,407 patientsRonen Arbel, Lior Rokach, Talish Razi, et al.
Journal of Clinical Medicine|January 10, 2026
The Effect of ADHD Stimulant Treatment on Weight Categories in Children and AdolescentsShlomit Yaron, Ronen Arbel, Talish Razi, et al.
Pageof 6